News headlines about OraSure Technologies (NASDAQ:OSUR) have trended somewhat positive this week, Accern reports. The research group identifies positive and negative news coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. OraSure Technologies earned a coverage optimism score of 0.19 on Accern’s scale. Accern also assigned headlines about the medical instruments supplier an impact score of 46.1021886963629 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.

These are some of the headlines that may have impacted Accern’s scoring:

OraSure Technologies (NASDAQ:OSUR) opened at $19.39 on Thursday. The stock has a market cap of $1,180.00, a P/E ratio of 37.29, a PEG ratio of 4.58 and a beta of 1.27. OraSure Technologies has a 52 week low of $8.39 and a 52 week high of $23.01.

OraSure Technologies (NASDAQ:OSUR) last issued its quarterly earnings data on Wednesday, November 1st. The medical instruments supplier reported $0.09 earnings per share for the quarter, meeting the Zacks’ consensus estimate of $0.09. The company had revenue of $42.30 million for the quarter, compared to the consensus estimate of $40.87 million. OraSure Technologies had a net margin of 20.48% and a return on equity of 14.12%. The firm’s revenue for the quarter was up 31.0% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.11 earnings per share. equities analysts expect that OraSure Technologies will post 0.43 earnings per share for the current fiscal year.

Several brokerages have recently issued reports on OSUR. Zacks Investment Research upgraded shares of OraSure Technologies from a “hold” rating to a “buy” rating and set a $25.00 target price on the stock in a research note on Wednesday, September 20th. ValuEngine downgraded shares of OraSure Technologies from a “buy” rating to a “hold” rating in a research note on Thursday, November 2nd. Jefferies Group downgraded shares of OraSure Technologies from a “buy” rating to a “hold” rating in a research note on Thursday, November 2nd. BidaskClub upgraded shares of OraSure Technologies from a “hold” rating to a “buy” rating in a research note on Thursday, December 21st. Finally, Canaccord Genuity reiterated a “buy” rating and issued a $22.00 target price on shares of OraSure Technologies in a research note on Tuesday, September 19th. Three analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $19.65.

In related news, Director Mara G. Aspinall acquired 5,000 shares of the stock in a transaction that occurred on Tuesday, November 7th. The shares were bought at an average price of $14.23 per share, for a total transaction of $71,150.00. Following the completion of the transaction, the director now directly owns 5,000 shares in the company, valued at $71,150. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 6.40% of the stock is owned by corporate insiders.

TRADEMARK VIOLATION NOTICE: “OraSure Technologies (OSUR) Getting Somewhat Favorable News Coverage, Analysis Finds” was first published by Watch List News and is the sole property of of Watch List News. If you are reading this piece of content on another domain, it was illegally copied and reposted in violation of U.S. and international copyright & trademark legislation. The correct version of this piece of content can be viewed at

OraSure Technologies Company Profile

OraSure Technologies, Inc (OraSure) is involved in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types.

Insider Buying and Selling by Quarter for OraSure Technologies (NASDAQ:OSUR)

Receive News & Ratings for OraSure Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies and related companies with's FREE daily email newsletter.